Transfusion-Associated Graft-Versus-Host Disease
Keywords:
-Abstract
-
Downloads
References
Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 19990,323315~21.
Ferrara JLM, Antin JH. The pathophysiology of graftversus-host disease. In: Hematopoietic Cell Transplantation. ED Thomas KG Blume, SJ Forman, eds. Oxford, UK: Blackwell Science 19999:305-15.
Greenbaum BH. Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991;9:1889-902.
Billingham RE. The Biology of Graft-versus-Host Reactions. New York: Academic Press, 1966:21-78.
Mathe' G, Bernard J, Schwarzenberg L. New trials with homologous bone marrow grafts after total irradiation in children with acute leukemia in remission. The problem of the secondary syndrome in man. Paris: Revues Hematologique, 1960;15,115-61.
Shimoda T. On postoperative erythroderma (In Japanese). Geka, 1955;17:487-92.
Aoki Y, Nakamura H, Sakakibara Y. Probable graft-versus- host reaction following massive blood transfusion in an aged patient with postoperative aortic aneurysm: a case report. Nippon Naika Gakkai Zasshi 1984;73:1209-16.
Anderson K. Transfusion-associated graft-versus-host disease. In: Ferrara JLM, Deeg Joachim H, Burakoff SJ, eds. Graft-vs-Host Disease, 2nd edition, revised and expanded. New York: Marcel Dekker 1997;587-606.
Kessinger A, Armitage JO, Klassen LW, Landmark JD, Hayes JM, Larsen AE, Purtilo DT. Graft versus host disease following transfusion of normal blood products to patients with malignancies. J Surg Oncol, 1987;36:206-9.
Otsuka S, Kunieda K, Hirose M, Takeuchi H, Mizutani Y, Nagaya M, Sato G, Kasuya S, Matsutomo K, Noma A, Saji S. Fatal erythroderma (suspected graft-versus-host disease) after cholecystectomy. Retrospective analysis. Transfusion, 1989;29:544-8.
Spitzer TR, Cahill R, Cottler FM, Treat J, Sacher R, Deeg HJ. Transfusion-induced graft-versus-host disease in patients with malignant lymphoma. A case report and review of the literature. Cancer 1990;66:2346-9.
von Fliedner VE, Higby DJ, Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med 1982;72:951-61.
Haga Y, Soma Y, Kawada K, Misumi T, Inoue T, Ikeda Y. Two cases of postoperative erythroderma. Keio J Med 1989;38:177-83.
Ohto H, Yasuda H, Noguchi M, Abe R. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion 1992;32:691-3.
Petz LD, Calhoun L, Yam P, Cecka M, Schiller G, Faitlowicz AR, Herron R, Sayah D, Wallace RB, Belldegrun A. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993;33:742-50.
Mincheff M. Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Vox Sanguinis 1998;74:189-200.
Chang H, Voralia M, Bali M, Sher GD, Branch DR. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. British J Haematology 2000;1111:146-56.
Ford JM, Cullen MH, Lucey JJ, Tobias JS, Lister TA. Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet 19761167-9.
Juji T, Takahashi K, Shibata Y, Ide H, Sakakibara T, Ino T, Mori S. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan (letter). NEngl J Med 1989;321:56.
Orlin JB, Ellis MH. Transfusion-associated graft-versus-host disease. Curr Opin Hematol 1997;4:442-8.
Ohto H, Anderson KC. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transf Med Review 1996,10:31-43.
Yasuura K, Okamoto H, Matsuura A Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg (Torino) 2000;41:377-80.
Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion 1995;35:284-91.
Ito K, Fujita M, Norioka M, Yoshida H, Arii S, Tanaka J, Tobe T, Kakuyama M, Maruya E, Saji H. Postoperative erythroderma with change of HLA phenotypes from heterozygotes to homozygotes: a report of two cases. European J Haematology 1991;46217-22.
Benson K, Marks AR, Marshall MJ, Goldstein JD. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Transfusion 1994;34:432-7.
Nishimura M, Uchida S, Mitsunaga S, Yahagi Y, Nakajima K, Tadokoro K, Juji T. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Blood 1997;89:1440-5.
Brubaker DB. Transfusion-associated graft-versus-host disease. Human Pathology 1986;17:1085-8
Hentschel R, Broecker EB, Kolde G. Intact survival with transfusion-associated graft-versus-host disease proved by human leukocyte antigen typing of lymphocytes in skin biopsy specimens. J Pediatrics 1995;126:61-4.
Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Hematopoietic Cell Transplantation. ED Thomas, KG Blume, SJ Forman, eds. Oxford, UK: Blackwell Science 19999:248-63.
Drobyski W, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, Gottschall J, Ash RC. Third-partymediated graft rejection and graft-versus-host disease after T-cell depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989;74:2285-94.
Hayakawa S, Chishima F, Sakata H, Fujii K, Ohtani K, Kurashina K, Hayakawa J, Suzuki K, Nakabayashi H, Esumi M, Nemoto N, Sakurai I, Satoh K. A rapid molecular diagnosis of posttransfusion graft-versus- host disease by polymerase chain reaction. Transfusion
;33:413-7.
Kunstmann E, Bocker T, Roewer L, Sauer H, Mempel W, Epplen J'T. Diagnosis of transfusion-associated graftversus-host disease by genetic fingerprinting and polymerase chain reaction. Transfusion 1992;32:766-70.
Lee TH, Donegan E, Slichter S, Busch MP. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 1995;85:1207-14.
Douglas SD, Fudenberg HH. Graft-versus-host reaction in Wiskott-Aldrich syndrome: antemortem diagnosis of human GVH in an immunologic deficiency disease. Vox Sanguinis 1969;16:172-8.
Ohto H, Anderson KC. Post-transfusion graft-versus-host disease in Japanese newborns. Transfusion 1996a;36:117-23.
Prince M, Szer J, van der Weyden MB, Pedersen JS, Holdsworth RF, Whyte G. Transfusion associated graft-versus-host disease after cardiac surgery: response to antithymocyte-globulin and corticosteroid therapy. Australian and New Zealand J Med 1991:21:43-6.
Ryo R, Saigo K, Hashimoto M, Kohsaki M, Yasufuku M, Watanabe N, Okada M, Tadokoro K, Juji T. Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. Vox Sang 1999;76:241-6.
Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83-9.
Luban NL. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol 2001;4(Suppl 11):34-45.
Funkhouser AW, Vogelsang G, Zehnbauer B, Tunnessen WW, Beschorner WE, Sanders M, Graeber JE, Goodnough LT, Johnston MF, Ramsey G, Sayers MH, Eisenstadt RS, Anderson KC, Rutman RC, Silberstein LE. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. Annals of Thoracic Surgery 1990;50:675-83.
Asai T, Inaba S, Ohto H, Osada K, Suzuki G, Takahashi K, Tadokoro K, Minami M. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs-host disease in Japan. Transfusion Medicine 2000:10:312-20.
Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999;39:128-34.
Lowenthal RM, Challis DR, Griffiths AE, et al. Transfusion-associated graft-versus-host disease: report of an occurrence following the administration of irradiated blood. Transfusion 1993;33:524-9.
Menitove JE. Standards for Blood Banks and Transfusion Services, 19th eds. Bethesda, MD. Am Assoc Blood Banks, 1999.
BCSH Blood Transfusion Task Force Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfusion Medicine 1996;6:261-71.
Akahoshi M, Takanashi M, Masuda M, Yamashita H, Hidano A, Hasegawa K, Kasajima T, Shimizu M, Motoji T, Oshimi K, Mizoguchi H. A case of transfusion-associated graftversus- host disease not prevented by white cell-reduction filters. Transfusion 1992;32:169-
Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfusion Medicine 2001;11:149-75.72.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
